Clinical Research Site

Boston, Massachusetts 02215

6 studies enrolling now · 19 studies all time

What they study most

ADHD, Binge-Eating Disorder, Depression, Excessive Sleepiness, Fibromyalgia, Hidradenitis Suppurativa, Major Depressive Disorder, Migraine, PNH, Paroxysmal Nocturnal Hemoglobinuria, Shift-work Disorder, Treatment Resistant Depression

Studies at this site

• Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol — Recruiting now
• Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design — Recruiting now
• Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN) — Recruiting now
• A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms — Recruiting now
• Open-Label Safety Study of AXS-14 in Subjects With Fibromyalgia — Enrolling by invitation
• Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS) — Completed
• Initiating Early Control of Migraine Pain and Associated Symptoms — Completed
• Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE) — Stopped early
• Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol — Completed
• Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE) — Completed
• Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder — Enrolling by invitation
• Hidradenitis Suppurativa Study of Izokibep — Stopped early
• Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT) — Completed
• Maximizing Outcomes in Treating Acute Migraine — Completed
• Open-Label Safety Study of AXS-05 in Subjects With Depression — Completed
• A Trial of AXS-05 in Patients With Major Depressive Disorder — Completed
• Mechanistic Evaluation of Response in TRD (MERIT) — Completed
• Ketamine for Major Depressive Disorder — Status unconfirmed